Compare · DNA vs MRNA
DNA vs MRNA
Side-by-side comparison of Ginkgo Bioworks Holdings Inc. (DNA) and Moderna Inc. (MRNA): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both DNA and MRNA operate in Biotechnology: Biological Products (No Diagnostic Substances) (Health Care), so they compete in similar markets.
- MRNA is the larger of the two at $25.42B, about 54.8x DNA ($463.9M).
- Over the past year, DNA is down 45.5% and MRNA is up 136.7% - MRNA leads by 182.2 points.
- MRNA has been more active in the news (10 items in the past 4 weeks vs 8 for DNA).
- MRNA has more recent analyst coverage (25 ratings vs 18 for DNA).
- Company
- Ginkgo Bioworks Holdings Inc.
- Moderna Inc.
- Price
- $7.22+0.28%
- $63.65+0.01%
- Market cap
- $463.9M
- $25.42B
- 1M return
- -19.72%
- -6.75%
- 1Y return
- -45.51%
- +136.69%
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Biotechnology: Biological Products (No Diagnostic Substances)
- Exchange
- NYSE
- NASDAQ
- IPO
- 2021
- 2018
- News (4w)
- 8
- 10
- Recent ratings
- 18
- 25
Ginkgo Bioworks Holdings Inc.
Ginkgo Bioworks Holdings, Inc. develops platform for cell programming. Its platform is used to program cells to enable biological production of products, such as novel therapeutics, food ingredients, and chemicals derived from petroleum. The company serves various end markets, including specialty chemicals, agriculture, food, consumer products, and pharmaceuticals. Ginkgo Bioworks Holdings, Inc. was founded in 2008 and is based in Boston, Massachusetts.
Moderna Inc.
Moderna, Inc., a biotechnology company, develops therapeutics and vaccines based on messenger RNA for the treatment of infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and auto-immune diseases. As of March 9, 2021, the company had 13 programs in clinical trials and a total of 24 development programs in six modalities comprising prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted and cell surface therapeutics, and systemic intracellular therapeutics. The company has strategic alliances with AstraZeneca PLC, Merck & Co., Inc., Vertex Pharmaceuticals Incorporated, Vertex Pharmaceuticals (Europe) Limited, the Biomedical Advanced Research and Development Authority, the Defense Advanced Research Projects Agency, the National Institute of Allergy and Infectious Diseases, the National Institutes of Health, the Coalition for Epidemic Preparedness Innovations, and Bill & Melinda Gates Foundation. Moderna, Inc. also has collaborations with Lonza Ltd. for the manufacture of COVID-19 vaccine; and Catalent Inc., Laboratorios Farmacéuticos Rovi, S.A., Recipharm, and Lonza Group for fill-finish manufacturing of its COVID-19 vaccine candidate, as well as Aldevron, LLC for supporting COVID-19 vaccine and additional programs in company's clinical development pipeline. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.
Latest DNA
- Ginkgo Bioworks downgraded by TD Cowen with a new price target
- SEC Form 10-Q filed by Ginkgo Bioworks Holdings Inc.
- Ginkgo Bioworks Holdings Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- SEC Form 4 filed by Large owner Canton Barry
- SEC Form 4 filed by Officer Shetty Reshma P.
- SEC Form 4 filed by Officer Kelly Jason R
- Ginkgo Bioworks Holdings Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits
- Officer Coen Steven P. converted options into 1,486 shares and sold $5,943 worth of shares (752 units at $7.90), increasing direct ownership by 1% to 51,438 units (SEC Form 4) (tax liability)
- SEC Form 4 filed by Director Henry Christian O
- SEC Form 4 filed by Director Fubini Ross
Latest MRNA
- SEC Form SCHEDULE 13G filed by Moderna Inc.
- Chief Executive Officer Bancel Stephane exercised 751,715 shares at a strike of $19.15 and sold $28,715,011 worth of shares (499,246 units at $57.52) as part of a pre-agreed trading plan, increasing direct ownership by 4% to 6,440,260 units (SEC Form 4) to satisfy withholding tax
- Amendment: SEC Form SCHEDULE 13G/A filed by Moderna Inc.
- Moderna Receives U.S. FDA Approval for Influenza Vaccine mFLUSIVA
- SEC Form 144 filed by Moderna Inc.
- Moderna Announces Initiation of Phase 1 Clinical Trial of mRNA-1469, Moderna's Investigational Vaccine Against Bundibugyo Ebolavirus
- SEC Form 10-Q filed by Moderna Inc.
- Moderna Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Moderna Reports Second Quarter 2026 Financial Results and Provides Business Updates
- Amendment: SEC Form SCHEDULE 13G/A filed by Moderna Inc.